01/13/2017
Craig Lindsley, Ph.D., a leader of Vanderbilt University School of Medicine’s groundbreaking drug discovery program, is the 2017 recipient of the Pharmacia-ASPET Award in Experimental Therapeutics from the American Society for Pharmacology and Experimental Therapeutics (ASPET).
In a news release, ASPET said Lindsley was honored for “his pioneering use of technology-enabled synthesis, which led to fundamental and transforming effects on medicinal chemistry, pharmacology, and drug discovery.” The award will be presented April 22 during ASPET’s annual meeting in Chicago. Read the whole article here.
Craig Lindsley's available technologies:
-
Novel PLD Inhibitors
-
Small Molecule Theraputics That Target the Muscarinic Acetylcholine Receptor 1 For The Treatment of Alzheimer's Disease
-
Small Molecule Mediated Transcriptional Induction of E-Cadherin and Inhibition of Epithelial-to-mesenchymal Transition
-
Novel Anti-Platelet Therapy for the Treatment of Thrombosis and Cerebrovascular Injury by Targeting PAR-4
-
Small molecule GlyT1 inhibitors as therapeutics for Schizophrenia or Parkinson's disease
-
mGlu4 PAMs as selective small molecule therapeutics totreat Parkinson's disease
-
mGlu3 NAMs as Therapeutics for Chemoresistant Tumors
-
Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders